Efficacy and safety of anlotinib hydrochloride combined with concurrent radiotherapy in the treatment of locally advanced cervical cancer: a single-arm, single-center, exploratory, phase II clinical study.

ABSTRACT:

Objective

This study aims to evaluate the therapeutic efficacy and safety of anlotinib, a multitarget tyrosine kinase inhibitor, combined with radiotherapy in patients with locally advanced cervical cancer (LACC).

Methods

A prospective single-center study enrolled 62 eligible LACC patients (intention-to-treat [ITT] population) between May 2023 and January 2024, with 53 completing the full treatment course (per-protocol [PP] population). Patients received anlotinib (10 mg/day, days 1-14, 21-day cycles) combined with intensity-modulated radiotherapy (IMRT) and intracavitary brachytherapy. Efficacy was assessed using RECIST v1.1 criteria, including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Safety was evaluated by monitoring

SUBMITTER: Liu H 

PROVIDER: S-EPMC12676224 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature